Abstract:This narrative review appaises the current pharmacological options for the treatment of obesity, with an emphasis on medications directed at incretin and hormonal receptors. These have experienced increased popularity. Direct and indirect mechanisms of action, efficacy, side effect profiles, and use in clinical practice are discussed. Future directions should optimize patient selection to maximize efficacy and minimize adverse effects. Summary Background Obesity has reached epidemic proportions, with >40% of the US population affected. Although traditionally managed by lifestyle modification, and less frequently by bariatric therapies, there are significant pharmacological advancements. Aims To conduct a narrative review of the neurohormonal and physiological understanding of weight gain and obesity, and the development, clinical testing, indications, expected clinical outcomes, and associated risks of current FDA‐approved and upcoming anti‐obesity medications (AOMs). Methods We conducted a comprehensive review in PubMed for articles on pathophysiology and complications of obesity, including terms 'neurohormonal', 'obesity', 'incretin', and 'weight loss'. Next, we searched for clinical trial data of all FDA‐approved AOMs, including both the generic and trade names of orlistat, phentermine/topiramate, bupropion/naltrexone, liraglutide, and semaglutide. Additional searches were conducted for tirzepatide and retatrutide ‐ medications expecting regulatory approval. Searches included combinations of terms related to mechanism of action, indications, side effects, risks, and future directions. Results We reviewed the pathophysiology of obesity, including specific role of incretins and glucagon. Clinical data supporting the use of various FDA‐approved medications for weight loss are presented, including placebo‐controlled or, when available, head‐to‐head trials. Beneficial metabolic effects, including impact on liver disease, adverse effects and risks of medications are discussed, including altered gastrointestinal motility and risk for periprocedural aspiration. Conclusion AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction‐associated steatotic liver disease.

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

New insights into the treatment of obesity.

New pharmacological approaches for obesity management

Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

Pharmacotherapy of obesity - benefit, bias and hyperbole.

Current pharmacotherapy for obesity

Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management

Comprehensive Review of Current and Upcoming Anti-Obesity Drugs

Pharmacologic management of obesity: Updates on approved medications, indications and risks

Obesity medications: A narrative review of current and emerging agents

Obesity Pharmacotherapy: Current Perspectives and Future Directions

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Future directions in obesity pharmacotherapy

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

The role of incretin receptor agonists in the treatment of obesity

Latest approaches for the treatment of obesity

Obesity medications in development

Pharmacologic options for the treatment of obesity

A concise review on the therapeutics of obesity